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Background and Introduction
For decades, patients, doctors, ethicists, and other interested parties have debated
the economics of the pharmaceutical industry. What is the best way to get
medications and related products to the people who need them, regardless
of their ability to pay for these drugs? Can prices can be lowered without
jeopardizing basic research for new drugs? Are pharmaceutical company pricing
practices monopolistic? What are the legal and ethical obligations related to
drugs developed—partially or fully—with public funds?
The Population Council convened a daylong

products. The purpose of the Day of Dialogue

meeting of an eminent group of academics, scientists,

was to explore ways of getting medicinal

representatives from the nonprofit sector, the pharma-

products—especially those invented and developed

ceutical industry, foundations, and government donor

partially or fully using public funding—into the

agencies, and practicing lawyers and doctors—all of

hands of the poor people of the world, wherever

whom have some connection with pharmaceutical

they live.

Economics of Pharmaceutical R&D and Pricing
The day opened with a presentation by F.M. Scherer, Emeritus Harvard
University John F. Kennedy School of Government professor and current
lecturer at Princeton’s Woodrow Wilson School, on the economics of
pharmaceutical research and development and product pricing.
extend patent protection—rather than to develop drugs

Scherer’s analysis of profits from pharmaceutical sales

to treat diseases that have few or no treatments available.

and investments in research and development (R&D)
showed that when profits increase, so does R&D. This

Pharmaceutical R&D is a risky business, with

suggests that pharmaceutical companies engage in what

7 out of 10 new drug entities failing to recover their

economists call “virtuous rent-seeking.” However, said

R&D costs. To fill otherwise depleted new product

Scherer, there is still cause for concern. Most R&D is for

pipelines, the drug industry is relying to an increasing

diseases prevalent in industrialized countries, not those

extent on publicly financed researchers at universities

in developing countries. And, while profits themselves

and nonprofit institutions, along with scientists at

drive R&D, the threat that a company will lose profits

biotech firms, to conduct much of the preclinical

(via patent expiration, for example) also drives R&D.

research. Thus, drug companies’ preclinical outlays, as a

The percentage of prescriptions filled with generic ver-

percentage of total discounted R&D outlays for new

sions of drugs whose patents have lapsed rose from 18

drugs, have declined, from 61 percent in the 1970s to 42

percent in 1980 to 48 percent in 2000. Another problem

percent in the 1990s.

is a tendency to develop “me too” drugs—modified

Scherer argued—and many participants agreed—that

mimics of existing medications that are designed to

two types of entities are badly needed if drug prices are to
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However, one big stumbling block in developing

be held in check and if a greater variety of medicines are
to be made available: first, companies that can manage

products to address developing-world diseases is the cost

clinical trials (which are costly and complicated) for uni-

of clinical trials. Continuous, reliable funding is needed.

versities, nonprofit organizations, and biotech firms; sec-

The NIH previously provided this money, but is now

ond, institutions—like Walter Reed Army Medical Center

doing so less often. Large drug companies have shown

or the National Institutes of Health (NIH)—that can con-

some willingness to pay for trials, but will not offer

duct drug screening, which is currently a bottleneck.

much until the PPP model is proven.
One participant noted that in some countries there is

Participants stressed that a vital, undeveloped resource is
the chemical libraries owned by large pharmaceutical com-

a “use it or lose it” patent policy. A change of this sort,

panies; some of these molecules have been screened already.

or a variation thereof, in U.S. patent law might be help-

These libraries serve as the companies’ “life savings.”

ful in bringing promising but shelved compounds into

However, many companies may be interested in licensing

testing. Another participant pointed out that one of the

these drugs for developing-country uses as a way of

costliest and most time-consuming aspects of bringing

improving the image of an industry that has been

new drugs to market is the new drug application (NDA)

embroiled in difficulties. Negotiation with individual

process. She asked whether drug companies should pur-

companies would be required to gain access to these

sue Food and Drug Administration (FDA) or European

libraries. Public-private partnerships (PPPs), which team

Medicines Agency (EMEA) regulatory approval, or is

for-profit pharmaceutical companies with nonprofit enti-

approval outside the United States and the European

ties, may be an appropriate construct to bridge this gap.

Union acceptable?

Ethical Considerations in Public-Sector Pricing of Pharmaceutical Products
Arthur Caplan, chair of the University of Pennsylvania’s department of Medical
Ethics, explored the question, “Can ethics save pharma?” Caplan acknowledged
that NIH funding is limited and will remain so for a while. He stated that
those who seek innovation in drug availability and pricing will need to look to
the pharmaceutical companies.
Potential partners of pharmaceutical companies—

Big pharma may very well be interested in pairing
with nonprofits to bring medicines to the developing

nonprofits that would like to bring low-cost medications

world, but there are ethical issues that concern the indus-

to the developing world—must recognize and manage

try. For example, the University of Pennsylvania has just

these and other ethical problems of the industry. The

launched a project on ethics and vaccines. People on the

reputation of big pharma is bad in the U.S., worse in

industry side have said that they think there may be too

Europe, and worst in the developing world.
The poor image of the industry is the result of several

much risk in these ventures that is not handled by proper informed consent. Similarly, Caplan was asked by a

factors. Recent books by Marcia Angell, Jerome P.

pharmaceutical company about producing anti-malarial

Kassirer, Jerry Avorn, and others have demonized the

drugs. The company was concerned not with pricing,

industry. Drug prices are skyrocketing. And as some

but with being accused of exploitatively experimenting

consumers have purchased cheaper Canadian drugs, the

in the developing world.

industry has launched a campaign, which Caplan termed
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“ludicrous,” questioning the safety of Canadian drugs.

new drug. It will also limit television advertising to

He said the issue is the reliability of middlemen, not the

“appropriate audiences at appropriate times.”
(One participant defended DTC marketing in some

safety of what is sold in Canadian drug stores.

cases. The ParaGard® T 380A IUD is a great product, he

Revelations in 2004 and 2005 about a link between
antidepressants and suicide in children, harmful side

stated, but IUDs have a bad reputation in the U.S.

effects caused by Vioxx and other cox-2 inhibitor drugs,

because of the Dalkon Shield tragedy. “How do we get the

and other disclosures have further damaged the reputa-

word out to the public that this is a good product?” asked

tion of the industry. A recent Harris Poll found that only

the participant. DTC marketing is a promising approach.)

13 percent of Americans believe that the pharmaceutical

Finally, some kind of assessment and accountability

industry is “generally honest and trustworthy.” Its repu-

should be built into the system. Johnson & Johnson, for

tation has plunged faster than those of the tobacco, oil,

example, has set up its management structure so that

and managed care industries.

each drug in its portfolio has an “ethics manager.” This
policy sprang from concerns surrounding opioid medi-

“Pharma is a very tricky partner to partner with,” said
Caplan. “These ethics problems are going to get in the

cines, but it is a good way for any pharmaceutical com-

way, no matter how easy it is to get the products on the

pany to ensure that greater attention is paid to ethical

shelf.” He suggested several means of starting to dispell the

obligations surrounding all drug developments.
A participant inquired about the ethical obligations

demons that haunt the industry. Big pharma could undertake a public relations campaign and redouble its lobbying

that pharmaceutical companies have to their sharehold-

efforts. The most effective action, however, would be dra-

ers. How can a company defend its decision to share its

matic changes in pharmaceutical industry culture.

drug library, participate in a PPP, or contribute to other
ventures that do not increase profits but may help poor

Drug companies could rededicate themselves to the scientific foundations of the industry. They could register all

people? Caplan replied that suits are possible but that

clinical trials. When testing a new drug to treat a condition

helping the poor sometimes is essential to doing business

for which there are already existing medications, they could

in healthcare. He said companies in the healthcare sector

conduct clinical trials that compare the new drug to the

have particular duties to advance the public good that do

best available treatment rather than to a placebo.

not encumber other industries. There is also a public

The pharmaceutical industry could recommit itself to

relations value to these activities; they help to de-demo-

receiving ethical guidance—from data safety monitoring

nize the company and the industry. Finally, said Caplan,

boards (DSMBs) and institutional review boards (IRBs),

pharmaceutical companies that conduct research in

among others—on how it does research, marketing, and

developing countries are obligated to leave something

sales. (Drug companies should ensure that the composi-

behind, though not necessarily the drug. Companies, for

tion of these groups reflects the public interest and pub-

example, can take steps to improve the local infrastruc-

lic good.)

ture. Local partners and citizens should be enlisted in

The industry could stop its most criticized marketing

determining company obligations, and these promises

practices: direct-to-consumer (DTC) marketing and free

should be kept whether or not the product being tested

samples to physicians and patients. Some large drug com-

is found to be effective.

panies are already taking a step in this direction. On 13

There are different moral dynamics surrounding the

June 2005, for instance, Bristol-Myers Squibb announced

testing of treatments for illnesses and the testing of prod-

that it will refrain from direct-to-consumer advertising for

ucts for healthy people that are meant to keep them

a minimum of 12 months following the launch of any

healthy, such as microbicides, contraceptives, and vaccines.
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For these types of products, there may be serious repercus-

have to be made available, whether published in a jour-

sions if a clinical trial causes a single death. This may

nal, announced in a news release, or publicized in other

come into play with tests of a rotavirus vaccine, for exam-

ways. Companies and public health both suffer in the

ple, which may begin in Africa and Asia by the end of

long run if adverse findings are or seem to be hidden.
Another participant raised the issue of differential

2006. Bioethics has not done a good job in addressing this

pricing. When research is based on public funds, he said,

issue, contended Caplan.

there should be a different pricing structure, even when

Another participant pointed out that in addition to
ethical issues related to the development of molecules

the product is licensed to a for-profit pharmaceutical

and research in the field, drug companies need to invest

company. Others concurred that there are serious ethical

more in product introduction and post-marketing sur-

issues related to the pricing of drugs. For example,

veillance. She asked whether there is a role for public-

human papillomavirus (HPV) vaccines—which prevent

sector organizations to do that. Caplan agreed that bad

infection with the virus and, thus, also prevent cervical

post-marketing surveillance is an important ethical and

cancer—are likely to be blockbusters in developed

policy problem. Registering trials should be a condition

countries. They are also desperately needed in the

of working with journals, academic medical centers, uni-

developing world, but may not be widely available there

versities, and governments. There should be consensus

unless pricing barriers can be overcome. There is a tug of

on ethical trial design, and all outcomes of all trials—not

war going on in drug pricing, stated one participant.

just those for drugs that are eventually approved or mar-

The pharmaceutical industry and its investors want the

keted—should be electronically searchable and accessi-

highest price possible and the public sector does not

ble. Participants agreed that negative results from trials

want to pay anything.

The Bayh-Dole Act and Its Effect on the Availability of Products
Developed with U.S. Public Funding
Howard Bremer, J.D., a consultant in patent, licensing, and technology
transfers, is a widely acknowledged expert on the Bayh-Dole Act, which governs
the disposition of intellectual property resulting from research funded fully or
partially by the U.S. government. He presented information about the Act and
its effect on availability of products developed with U.S. public funding.
tion. Government agencies that funded the research often

Bayh-Dole is codified in 35 U.S.C. § 200-212 and is
implemented by 37 C.F.R. 401. Prior to the enactment of

did not pursue the commercialization of the products

the legislation in 1980, the United States government

either. Accordingly, the number of patents issued each year

retained intellectual property rights to any invention creat-

on technology that was the direct result of federally sup-

ed as a result of government-funded research, regardless of

ported research declined steadily for several years prior to

the amount of government funding. This circumstance

the enactment of the law. As a result, products based on

contributed to the loss of a technological advantage that

government-funded research never reached the public.
Bayh-Dole was designed specifically to address this

the United States had previously held in the world. Because
organizations did not own the rights to their inventions,

roadblock. It allows universities, businesses, and

they had no incentive to pursue them to commercializa-

nonprofits to retain rights to inventions they make or
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develop with federal funding. In exchange, these organi-

was enacted. The essence of the law is being emulated

zations are required, among other things, to promote

around the world: in Germany, Japan, and elsewhere.

and attempt to commercialize such inventions. At the

Regarding the march-in rights, one participant puz-

time the legislation was first proposed, there was some

zled over the government’s interpretation of the wording

criticism of it. Some senators opposed it on the basis that

in Bayh-Dole. The law states that the government can

“if the taxpayer funds the research, the taxpayer should

march in when “action is necessary to alleviate health or

own the ideas produced.” However, in practice this

safety needs which are not reasonably satisfied by the

approach had led to a situation in which “the taxpayers

contractor, assignee, or their licensees.” The participant

were getting no benefit whatsoever,” according to

asked rhetorically whether health needs are being

Senator Birch Bayh, co-sponsor of the Act.

reasonably satisfied when the price of a drug is raised by
a factor of five (as happened with Norvir).

As a safeguard against noncompliance with the

The government must be very careful, though, not to

requirements of the Act, the government reserved
“march-in rights.” Under very specific circumstances—

exercise march-in rights hastily, noted another partici-

for example, if the inventing organization does not

pant. Innovation would be discouraged if organizations

actively promote and attempt to commercialize its inven-

thought that patents would be taken away if they accept-

tion or if action is needed to protect the health and safe-

ed government funds.
The exercise of march-in rights is not likely to be

ty of consumers—these march-in rights require the
inventor to grant licenses for the invention to responsible

undertaken to correct drug prices, argued another partic-

applicants, on terms that are reasonable under the cir-

ipant. All administrations are pro-business and there is

cumstances. If the inventor refuses such a request, the

no benefit for businesses in controlling private-sector

government is allowed to grant such licenses itself.

prices. We would like companies to do good and do
well. Companies should make some money—though

Some observers have argued that the Bayh-Dole Act
states that inventions produced by government funding

little—in the public sector. They should not have to

must be made available to the public at a “reasonable

give their products away. If there is no profit, what is a

price.” However, this contention has been publicly refut-

reasonable return for selling it in the public sector only?

ed by Senators Bayh and Robert Dole, the co-sponsors

What is a reasonable negotiation?
In answer to this, one participant stated his belief

of the legislation, and by experts in patent law, including
Bremer. In 2004, the National Institutes of Health was

that all licensing agreements should have some language

petitioned to exercise march-in rights on the basis of the

guaranteeing public-sector pricing. There must be

cost of a drug (Norvir, a protease inhibitor used to treat

some agreement at the outset that the price will be

HIV infection). However, to date, no federal agency has

cost, plus a small amount. Some other participants

exercised these rights.

strongly disagreed that such an approach is feasible.
One stated, “there are many factors that go into that

One participant asked about the mechanism for ethical oversight now that universities and other research

decision and to assume that it can be set at the outset

organizations stand to profit from their research. Bremer

is perhaps naïve.” Another noted that to have the terms

answered that most universities have established conflict-

set at the outset might present some problems.

of-interest groups to alleviate perceived and real conflicts

“Confidentiality. Deals change. I would offer as a

of interest. The Bayh-Dole Act is supposed to ensure

consideration that it’s good to have an idea of where you

that the public benefits from federally funded research.

want to get but you have to understand the nature of

The law, says Bremer, is as viable today as it was when it

business agreements.”
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Another participant concurred, stating that such a

“We had in our collaborations reasonable pricing clauses

simplistic approach carries the assumption that there is a

but we found that they drove away potential collabora-

one-to-one ratio between patent and product. In fact,

tors,” he said. “It was more effective to drop that clause

treatments typically are based on a number of patents

and try to facilitate tiered royalty rates, or to put in lan-

often held by a variety of organizations. Adjuvants, drug

guage for indigent access programs.”

ingredients whose function is to facilitate or modify the

In addition to providing drugs at low cost to people in

action of the principal ingredient, are cross licensed, for

the developing world, some participants argued forcefully

example. Nonprofit institutions and universities do not

for products to be made available to low-income people in

usually have the rights to all the pieces, or even the pri-

the United States, noting that the poor in the U.S. are

mary piece of a therapy. “We are committed to providing

often overlooked. Other participants disagreed with this

low-cost drugs, but there are tons of constraints and our

point of view, saying that it would be unfair for the

negotiating position is weak.”

wealthy U.S. to “throw their poor into the same basket” as
poverty-stricken people in the developing world. A heated

One participant gave the example of his institution’s

debate ensued and no consensus was reached.

attempt to guarantee low prices for the public sector.

Alternative Models of Differential Pricing for Medicines
The final segment of the day featured a videotape of Patricia M. Danzon, Professor
of Health Care Systems and Insurance and Risk Management at the University of
Pennsylvania Wharton School, presenting a talk on differential drug pricing through
confidential rebates. Discussion of the video was moderated by Ernst R. Berndt,
Professor of Applied Economics at the Massachusetts Institute of Technology Sloan
School of Management and the National Bureau of Economic Research.
ized countries and where middle-income countries

The question of differential pricing has emerged in
two contexts. One is making existing drugs, particularly

would fit. Danzon’s presentation focused on an

HIV/AIDS drugs, affordable and available in developing

innovative strategy for providing price differentials in

countries. Additionally, in the U.S. there have been con-

various settings.
Companies’ ability to provide differential prices has

cerns about “parallel trade,” the importation of drugs
from countries where prices are low to countries where

been eroded by two phenomena. First, parallel trade

prices are high.

and, second, extensive referencing by governments that
regulate their prices based on prices in other countries.

As mentioned earlier in the meeting, there is general
agreement that the prices paid in poorer countries

A study conducted by Danzon found that drug price dif-

should be lower than the prices paid in richer countries

ferentials relative to per capita income were roughly

(although there is no consensus about what the appro-

appropriate within the industrialized or more affluent

priate differentials are or how to implement them).

countries, but for the two middle-income countries in

However, there is less agreement as to what the differ-

her study—Mexico and Chile—prices were out of line

ential pricing should be within and among industrial-

relative to per capita income.
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M I R E N A ®: I M P R O V I N G A C C E S S T O A N E W P R O D U C T

Discussion arose among participants about ways to make Mirena® more accessible
to women in developing countries and to poor women in the United States.

M

irena is a levonorgestrel-releasing

intrauterine system (IUS) that was

developed by Population Council biomedical
researchers with some government funding.
Mirena is licensed to Schering AG and mar-

keted in the United States by its subsidiary,

Berlex Inc. The IUS is registered as a contraceptive in more than 100 countries and is

available on all continents; it was approved
for use in the United States in December

2000. It combines the best features of hormonal contraceptives and intrauterine

devices (IUDs), delivering the progestin levo-

norgestrel directly to the uterus and providing
highly effective contraception for up to

five years. Mirena also reduces bleeding,

including the excessive menstrual bleeding
experienced by some women. One partici-

International Contraceptive Access [ICA]

level challenges may need to be addressed.

women. In 2005, the ARCH Foundation pro-

to replace the Copper T 380A IUD (a popular

Foundation) to provide Mirena to low-income
vided more than 12,000 Mirena units to poor
women in the United States, and in 2006 it
will provide 13,000. Schering AG has allo-

cated approximately 150,000 Mirena units to
the ICA Foundation through 2006; approxi-

mately 37,000 of these are at no charge and
the remainder are at a very low price. The
Foundation has transferred 3,800 units to
public-sector agencies in Ecuador at no

cost, where it has also sponsored insertion

of two independent foundations (Berlex cre-

ated the ARCH Foundation, operating solely
in the U.S., and Schering created the

major problems with staffing, distribution

capacity, and other issues. One attendee

argued that these foundations provide a way
to learn about the issues, but ultimately may
not be the best mechanism for widespread
distribution to poor women.

There was further debate about the cost

was not discussed, one attendee expressed

cies in Nigeria, Kenya, and Indonesia.

One participant contended that the foun-

they are set up to provide. Another attendee

In its licensing agreements the

The health systems themselves may have

ies with and transferring free units to agen-

thus making Mirena doubly important in the

Population Council arranged for the creation

also developed by the Population Council).

to manufacture Mirena. Although the current

the process of sponsoring training and stud-

dations are distributing only token numbers

developing world.

nonhormonal contraceptive product that was

training and introductory studies. It is also in

pant noted that this decrease in menstrual

bleeding greatly reduces the risk of anemia,

Local agencies, for example, may not want

of Mirena and are not meeting the need that
countered that these foundations are “priming the pump.” Since Mirena is a relatively

new product, the demand for it in the devel-

oping world is comparatively low. An informa-

tion campaign is needed to raise its profile.
Even in places where it is available, local-

cost to produce an individual unit of Mirena

his belief that it would be possible to manufacture the product for less than 10 dollars
per unit. Another participant noted other

costs associated with Mirena, among them
provider training, preinsertion pregnancy

tests, and insertion of the device. A third participant said that in frustration her foundation

had considered developing a low-cost generic version of Mirena, but would prefer that
Mirena itself could be made more readily
available to poor women.

There is no consensus on which approach is eco-

There are two currently discussed approaches to achieving differential pricing. One is a system of mandated dis-

nomically appropriate and politically acceptable. And,

counts calculated as a percentage off some benchmark

even if governments could agree, there is no guarantee

price (the EU Commission proposed a 75 percent dis-

that companies would be willing to supply drugs at

count off the average OECD price, restricted to drugs

these prices. This is the case in part because price dif-

for treating certain diseases, such as HIV/AIDS, malaria,

ferentials would be visible and, thus, the threat of par-

and tuberculosis). The other approach is a markup, per-

allel trade and of external referencing would remain.

haps 15 percent, based on marginal cost. But this raises

Furthermore, having a set of regulated prices would

the question of which marginal cost. What if additional

establish certain benchmarks and discourage competi-

production capacity is required, for example?

tion below those prices.
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ences within the industrial world where there are real dif-

Danzon and her colleagues have proposed a system of

ferences in income.

achieving differential prices by permitting and encourag-

One participant commented that “loose lips” could

ing confidential rebates. In this system, manufacturers
would sell their products to wholesalers who would then

sink the confidential rebate system by allowing for par-

distribute the drugs at a uniform price worldwide. The

allel trade. Other attendees suggested additional innova-

manufacturers would negotiate rebates with the final

tive approaches. They acknowledged that a challenge

purchasers and these rebates would be paid conditional

that needs to be addressed is that U.S. law stipulates

on purchases being made. This is the same model that is

that the government gets the lowest offered price.

used in the U.S. in which HMO benefit managers nego-

Genzyme circumvents this issue by either charging full

tiate different discounts with manufacturers and those

price for its drugs or giving them away. Another partici-

rebates are made electronically. The manufacturers sell at

pant proposed that pharmaceutical companies should

a uniform price but price differentials exist because of

have to decide in advance whether they are going to sell

these rebates.

their products in the developed or the developing world.
If they are going to sell in the developed countries, they

With this system, price differences are not observable
to other people. Thus, manufacturers are able to give

would lose all patent protection in the developing coun-

lower prices to low-income countries, knowing that

tries, and this would allow for the manufacture of inex-

those prices will not spill over to the high-income coun-

pensive, generic versions of the drugs. Another partici-

tries. That ability to segment markets is assured because

pant suggested that a way to encourage companies to

parallel trade and external referencing are not possible.

work on treatments for tropical diseases would be for

This system is flexible across drugs and countries. It also

foundations or governments to make advance purchase

encourages competition.

commitments.

The primary objection to the idea of confidential

In its licensing agreements, the Population Council

rebates is that developing countries lack the bargaining

arranged for the creation of two foundations to provide

power to negotiate them. However, Danzon suggested

its Mirena® intrauterine contraceptive system to low-

that third parties (e.g. nongovernmental organizations

income women. Under its Mirena contract, Berlex Inc.,

or governments) bargain on behalf of consumers in

established the not-for-profit ARCH Foundation to

low-income countries and that part of this bargaining

assist low-income women in the United States who do

could include price-volume contracts. In this sort of

not have insurance coverage for Mirena. Schering AG

system, if demand is really price sensitive, it is in the

and its Finnish subsidiary, Schering Oy—the manufac-

interest of manufacturers to give deep discounts, pro-

turers of Mirena and its marketers outside the United

vided that those discounts do not then spill over to

States—have established the International Contraceptive

high-income markets.

Access (ICA) Foundation, which provides Mirena at

A second objection to this sort of system is that if

reduced prices to selected public-sector organizations in

prices are not observable, then the system is open to cor-

order to help serve the needs of poor women and

ruption. This is particularly a concern where subsidies

families, primarily in developing countries. The ICA

from various government agencies might be involved.

Foundation is the first foundation for the specific

This concern, however, can be addressed by arranging

purpose of supplying products at reduced prices interna-

for audits by a third party and the discounted prices

tionally. Controversy over the availability and cost of

would not be observable to governments in other coun-

Mirena in the developing world prompted a spirited

tries. This proposal applies equally well to price differ-

debate among workshop participants.
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Conclusion
It is possible to draw several conclusions from the day’s discussion about the
public-sector pricing of pharmaceutical products and the work that remains to
be done. Among them:
6. A major task is to find appropriate ways for donors

1. Big pharmaceutical companies possess chemical
libraries that may include compounds that could be

to subsidize important pharmaceutical products for

useful. (Several organizations in attendance are bene-

those unable to afford them.

ficiaries of donations of rights to such compounds.)

7. License agreements from publicly supported research
organizations can include reasonable pricing clauses,

2. Intermittent funding does not enable organizations

tiered royalty rates, and indigent access programs.

to pursue drug development; new approaches and
mechanisms are needed to assure consistent funding.

8. Funding of liability protection for not-for-profit
research entities is a significant concern that needs to

3. Clinical trials conducted in developing countries

be addressed with donor organizations.

need to benefit the local population; something
must be left behind, such as health infrastructure

9. As is the case with funding for development, fund-

improvement, if not a drug.

ing for commodity purchase must be consistent and
long-term in order for pharmaceutical companies to

4. The cost associated with taking a pharmaceutical
product from the point at which a publicly funded

commit the resources needed to supply the public

organization would license it to a pharmaceutical

sector; advance purchase commitments provide a

company to its market introduction is many times

mechanism.

larger than and far outweighs the cost and public

10. Getting new products to the dock at a low price in a

funding preceding licensing.

developing country does not solve the problem.
Product introduction, adequate distribution chan-

5. Pharmaceuticals are not widgets. Companies in this
industry have a greater societal responsibility than

nels, and infrastructure for delivery are also required.

companies in other industries.

Attending to these issues requires time and money.
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